Biotek-snakken — Januar 2023
-
Cantargia har jo fået voldsomme klø i 2022, som mange andre udbombede biotekaktier. Adgangen til kapital er blevet MEGET sværere og derudover fik den nok også lidt skattesalg klø i sidste halvdel af
året.
-
Kort video/
Pharma og biotek - opdatering fra debat og chat uge 1 - Novo Nordisk ' Zealand Pharma ' Genmab ' Bavarian Nordic ' Expres2ion ' AnavexHelge Larsen gennemgår det sidste nye om selskaberne inden for pharma og biotek ud fra den kvalificerede debat og chat på Proinvestor. https://www.proinvestor.com/boards/109254
-
BioNTech Partners With UK To Provide Up To 10,000 Patients With MRNA Cancer Immunotherapies By 2030 https://www.proinvestor.com/investornyt/923791/biontech-partners-with-uk-to-provide-up-to-10000-patients-with-mrna-cancer-immunotherapies-by-2030
-
Neil Josephson is out as CMO of Zymeworks after less than 14 months on the job as CEO Kenneth Galbraith continues to tinker with his C-suite lineup. You have to dig deep in this week’s corporate update to spot the changes at Zymeworks, which include Alder BioPharmaceuticals co-founder Jeffrey Smith stepping in as SVP, early-stage development. The Vancouver biotech, which bebopped its way to a zanidatamab collaboration with Jazz Pharmaceuticals worth $325 million upfront......
-
FDA Approves Eisai And Biogen's Leqembi For Alzheimer's Disease Treatment https://www.proinvestor.com/investornyt/924335/fda-approves-eisai-and-biogens-leqembi-for-alzheimers-disease-treatment
-
Eisai Submits SBLA To FDA For Traditional Approval Of Leqembi For Alzheimer's Disease Treatment https://www.proinvestor.com/investornyt/924336/eisai-submits-sbla-to-fda-for-traditional-approval-of-leqembi-for-alzheimers-disease-treatment
-
Lidt håb til Curevac i sidste uge https://finance.yahoo.com/news/curevac-n-v-nasdaq-cvac-120311976.html
-
2 Healthcare Stocks That Could Make You Richer
-
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc - Transaction expands Chiesi’s rare disease medicine portfolio - All cash acquisition at US$14.50 per ADS, plus Contingent Value Rights of up to an additional US$2.50 per ADS based on certain Filsuvez® milestones being achieved - Total Transaction value of up to US$1.48 Billion with upfront consideration representing a 107% premium to Amryt ADS’ closing price on January 6, 2023 - Transaction unanimously approved and recommended by the Boards
Yahoo Finance (finance.yahoo.com)
Lækkert med en dobbelt op på en pæn portion left overs fra Chiasma (som jo gik bort alt for tidligt) - håber flere er med her Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind